These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19147089)

  • 61. Myeloid neoplasms in the guise of nutritional deficiency.
    Parthasarathy V
    Case Rep Hematol; 2012; 2012():826939. PubMed ID: 23227377
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
    Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
    Lee JY; Hong WJ; Majeti R; Stearns T
    PLoS One; 2014; 9(3):e92641. PubMed ID: 24658090
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Quality of life in MPN comes of age as a therapeutic target.
    Scherber RM; Geyer HL; Mesa RA
    Curr Hematol Malig Rep; 2014 Dec; 9(4):324-30. PubMed ID: 25262210
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A myeloproliferative disorder may hide another one.
    Laibe S; Tadrist Z; Arnoulet C; Sainty D; Mozziconacci MJ
    Leuk Res; 2009 Aug; 33(8):1133-6. PubMed ID: 19250672
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.
    Galka-Marciniak P; Kanduła Z; Tire A; Wegorek W; Gwozdz-Bak K; Handschuh L; Giefing M; Lewandowski K; Kozlowski P
    Sci Rep; 2022 Jun; 12(1):10924. PubMed ID: 35764886
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical correlates of serum pro-major basic protein in a spectrum of eosinophilic disorders and myelofibrosis.
    Ho CL; Kito H; Squillace DL; Lasho TL; Tefferi A
    Acta Haematol; 2008; 120(3):158-64. PubMed ID: 19039208
    [TBL] [Abstract][Full Text] [Related]  

  • 69. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
    Kodali S; Chen C; Rathnasabapathy C; Wang JC
    Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
    [TBL] [Abstract][Full Text] [Related]  

  • 70. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
    Tefferi A; Pardanani A
    Blood Rev; 2011 Sep; 25(5):229-37. PubMed ID: 21742423
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Conventional cytogenetics in myelofibrosis: literature review and discussion.
    Hussein K; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Global cytokine analysis in myeloproliferative disorders.
    Ho CL; Lasho TL; Butterfield JH; Tefferi A
    Leuk Res; 2007 Oct; 31(10):1389-92. PubMed ID: 17328948
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Epidemiology of myeloproliferative neoplasms in the United States.
    Mehta J; Wang H; Iqbal SU; Mesa R
    Leuk Lymphoma; 2014 Mar; 55(3):595-600. PubMed ID: 23768070
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
    Valent P
    Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A case of Philadelphia chromosome positive myeloproliferative neoplasm in a pregnant woman with unusual primary myelofibrosis features.
    Koshy J; Alperin J; Jana B; Markowitz A; Qian YW
    Case Rep Hematol; 2013; 2013():702831. PubMed ID: 23781354
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mutant molecules of interest in myeloproliferative neoplasms: introduction.
    Tefferi A
    Acta Haematol; 2008; 119(4):192-3. PubMed ID: 18566535
    [No Abstract]   [Full Text] [Related]  

  • 78. Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm.
    Hussein K; Dralle W; Theophile K; Kreipe H; Bock O
    Ann Hematol; 2009 Apr; 88(4):325-32. PubMed ID: 18773208
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Imaging features of myeloproliferative neoplasms.
    Murphy IG; Mitchell EL; Raso-Barnett L; Godfrey AL; Godfrey EM
    Clin Radiol; 2017 Oct; 72(10):801-809. PubMed ID: 28615140
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Defining targets in myeloproliferative disorders: reflecting on what is important.
    Griesshammer M
    Hematol Oncol; 2009 Jun; 27 Suppl 1():2-4. PubMed ID: 19468984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.